Artemis Biosystems
Artemis Biosystems specializes in innovative bioprocessing solutions, particularly the VHU® Perfusion system, which significantly reduces manufacturing time and costs for viral vectors and vaccines. Their mission is to enable scalable, cost-effective production of gene therapy vectors and vaccines, advancing the field of biopharmaceutical manufacturing.
Industries
Nr. of Employees
small (1-50)
Artemis Biosystems
Cambridge, Massachusetts, United States, North America
Patents
Products
Perfusion viral harvest system (bench-to-commercial)
A perfusion filtration system designed to enable continuous or semi-continuous harvesting of viral vectors and viral-like particles from suspension cultures, intended for process intensification and scale-up (small bench units for DOE through systems intended to support up to reported ~2000 L scale).
In-line hyperspectral pH monitoring prototype (R&D)
Prototype system combining hyperspectral imaging and pre-trained deep learning models to enable in-line, non-invasive, self-calibrated pH (and related DO/glucose) measurements in bioprocesses.
Perfusion viral harvest system (bench-to-commercial)
A perfusion filtration system designed to enable continuous or semi-continuous harvesting of viral vectors and viral-like particles from suspension cultures, intended for process intensification and scale-up (small bench units for DOE through systems intended to support up to reported ~2000 L scale).
In-line hyperspectral pH monitoring prototype (R&D)
Prototype system combining hyperspectral imaging and pre-trained deep learning models to enable in-line, non-invasive, self-calibrated pH (and related DO/glucose) measurements in bioprocesses.
Services
Supply of bench-scale perfusion filtration systems intended for design-of-experiment studies and process optimization for viral vector and VLP production.
Technical consultation and support to evaluate perfusion-based process solutions from pilot to commercial scale for viral vector and vaccine manufacturing.
Participation in multi-institution consortia and grant-funded projects to develop scalable lentiviral manufacturing methods and inline monitoring systems.
Supply of bench-scale perfusion filtration systems intended for design-of-experiment studies and process optimization for viral vector and VLP production.
Technical consultation and support to evaluate perfusion-based process solutions from pilot to commercial scale for viral vector and vaccine manufacturing.
Participation in multi-institution consortia and grant-funded projects to develop scalable lentiviral manufacturing methods and inline monitoring systems.
Expertise Areas
- Viral vector manufacturing
- Vaccine manufacturing (VLPs)
- Perfusion bioprocessing
- Process intensification for suspension culture
Key Technologies
- Perfusion culture
- Filtration-based cell retention allowing virus-permeable harvest
- Process intensification to high cell density
- Transient transfection with PEI:DNA polyplexes
News & Updates
In 2019, Artemis Biosystems was awarded a grant by NIIMBL to develop a perfusion-based method for large-scale lentiviral vector manufacturing using VHU® technology.
In 2020, Artemis Biosystems received a NIIMBL grant to develop an in-line, self-calibrated pH monitoring system utilizing hyperspectral imaging and deep learning.
Artemis Biosystems was featured in GEN March 2020 edition discussing viral vector manufacturing and the impact of VHU® technology on reducing costs and manufacturing time.
In 2019, Artemis Biosystems was awarded a grant by NIIMBL to develop a perfusion-based method for large-scale lentiviral vector manufacturing using VHU® technology.
In 2020, Artemis Biosystems received a NIIMBL grant to develop an in-line, self-calibrated pH monitoring system utilizing hyperspectral imaging and deep learning.
Artemis Biosystems was featured in GEN March 2020 edition discussing viral vector manufacturing and the impact of VHU® technology on reducing costs and manufacturing time.